[go: up one dir, main page]

DK200301628A - NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components - Google Patents

NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components Download PDF

Info

Publication number
DK200301628A
DK200301628A DK200301628A DKPA200301628A DK200301628A DK 200301628 A DK200301628 A DK 200301628A DK 200301628 A DK200301628 A DK 200301628A DK PA200301628 A DKPA200301628 A DK PA200301628A DK 200301628 A DK200301628 A DK 200301628A
Authority
DK
Denmark
Prior art keywords
hiv
envelope protein
immunological properties
diagnosis
useful
Prior art date
Application number
DK200301628A
Other languages
Danish (da)
Inventor
Marc Alizon
Luc Montagnier
Denise Guetard
Pierre Sonigo
Mireille Guyader
Pierre Tiollais
Lisa Chakrabarti
Francois Clavel
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/003,764 external-priority patent/US5051496A/en
Priority claimed from FR8701739A external-priority patent/FR2610632B1/en
Priority claimed from FR8705398A external-priority patent/FR2614025B1/en
Priority claimed from DK200201277A external-priority patent/DK175879B1/en
Application filed by Pasteur Institut filed Critical Pasteur Institut
Priority to DK200301628A priority Critical patent/DK176372B1/en
Publication of DK200301628A publication Critical patent/DK200301628A/en
Application granted granted Critical
Publication of DK176372B1 publication Critical patent/DK176372B1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

New peptides (I) have immunological properties in common with those of the peptide skeleton of the envelope protein of HIV-2 and also have a peptide structure in common with that of SIV (simian immunodeficiency virus)-7 glycoprotein. Also new are (i) a sequence of 9600 nucleotides corresponding to the SIV genome (reproduced in the specification, together with derived amino acid sequence of viral proteins gag, pol, env, Q, X, R, tat, art and F genes) and its fragments; (2) recombinant DNA contg. all or part of the CDNA from this sequence inserted into a vector, and (3) antigenic and immunogenic conjugates contg. (I).

Description

PATENTKRAV 1. Antigenisk peptid gag1, kendetegnet ved, at det udviser en af basisstrukturerne:Patent claim 1. Antigenic peptide gag1, characterized in that it exhibits one of the basic structures:

XDCKLVLKGLGMNPTLEEMLTAZXDCKLVLKGLGMNPTLEEMLTAZ

XDCKLVLKGLGTNPTLEEMLTAZ hvori X og Z er OH eller NH2-grupper, eller når de immunologiske egenskaber af peptider befriet for disse grupper ikke modificeres væsentligt, kan X og Z betegne grupper omfattende 1-5 aminosyrerester, og hver af bindestregerne betegner en aminoacylrest valgt blandt sådanne, som muliggør, at det angivne peptid bevarer de immunologiske egenskaber fra en af de følgende sekvenser:XDCKLVLKGLGTNPTLEEMLTAZ wherein X and Z are OH or NH 2 groups or when the immunological properties of peptides liberated from these groups are not substantially modified, X and Z may represent groups comprising 1-5 amino acid residues and each of the hyphens represents an aminoacyl residue selected from such groups. which allows the specified peptide to retain the immunological properties of one of the following sequences:

DCKLVLKGLGMNPTLEEMLTADCKLVLKGLGMNPTLEEMLTA

DCKLVLKGLGTNPTLEEMLTA 2. Antigenisk middel indeholdende mindst et peptid gag1 ifølge krav 1 eller mindst en oligomer deraf, kendetegnet ved, at det er i stand til at genkendes af biologiske væsker af human oprindelse, især serum indeholdende anti-HIV-2 antistoffer og i en vis udstrækning anti-HIV-1 antistoffer. 3. Fremgangsmåde til in vitro diagnosticering af HIV-2 infektioner i en biologisk væske, kendetegnet ved, at man bringer den biologiske væske i kontakt med mindst et peptid ifølge krav 1 eller et konjugat af disse peptider med et bærermolekyle, og detekterer den eventuelle tilstedeværelse af et antigen-antistofkompleks i den biologiske væske ved hjælp af fysiske eller kemiske metoder. 4. Fremgangsmåde til in vitro diagnosticering af HIV-2 infektioner i en biologisk væske ifølge krav 3, kendetegnet ved, at detekteringen af det eventuelt dannede antigen-antistofkompleks gennemføres ved hjælp af immunoenzymatiske prøver (af typen ELISA), immunofluorescensprøver (af typen IFA), radioimmunologiske prøver (af typen RIA) eller radioimmu-nopræcipiteringsprøver (af typen RIPA). 5. Kit til in vitro diagnosticering af HiV-2 infektioner i en biologisk væske, kendetegnet ved, at det omfatter: et peptidisk middel indeholdende et peptid ifølge krav 1 eller en blanding af sådanne peptider eller et konjugat af disse peptider med et bærermolekyle, eller, et reagens til sammensætning af et medium, der er gunstigt for gennemførelsen af en immunologisk reaktion, et eller flere eventuelt mærkede reagenser til detektering af antigen-antistofkomplekset dannet ved den immunologiske reaktion, samt en biologisk referencevæske, der er fri for antistoffer, som genkendes af det nævnte peptidiske middel.DCKLVLKGLGTNPTLEEMLTA 2. Antigenic agent containing at least one peptide gag1 according to claim 1 or at least one oligomer thereof, characterized in that it is capable of being recognized by biological fluids of human origin, in particular serum containing anti-HIV-2 antibodies and in some extensive anti-HIV-1 antibodies. Method for in vitro diagnosis of HIV-2 infections in a biological fluid, characterized in that the biological fluid is contacted with at least one peptide according to claim 1 or a conjugate of these peptides with a carrier molecule, and detects any presence thereof. of an antigen-antibody complex in the biological fluid by physical or chemical methods. Method for in vitro diagnosis of HIV-2 infections in a biological fluid according to claim 3, characterized in that the detection of the possibly formed antigen-antibody complex is carried out by immunoenzymatic tests (type ELISA), immunofluorescence tests (type IFA) , radioimmunological specimens (RIA type) or radioimmunoprecipitation samples (RIPA type). A kit for in vitro diagnosis of HiV-2 infections in a biological fluid, comprising: a peptidic agent containing a peptide according to claim 1 or a mixture of such peptides or a conjugate of these peptides with a carrier molecule, or , a reagent for composition of a medium favorable for carrying out an immunological reaction, one or more optionally labeled reagents for detecting the antigen-antibody complex formed by the immunological reaction, and an antibody-free biological reference fluid which is recognized of said peptidic agent.

DK200301628A 1987-01-16 2003-11-03 NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components DK176372B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK200301628A DK176372B1 (en) 1987-01-16 2003-11-03 NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US376487 1987-01-16
US07/003,764 US5051496A (en) 1986-01-22 1987-01-16 Peptides related to human immunodeficiency virus II (HIV-2)
FR8701739A FR2610632B1 (en) 1987-02-11 1987-02-11 CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
FR8705398A FR2614025B1 (en) 1987-04-15 1987-04-15 PEPTIDES LIKELY TO BE RECOGNIZED BY ANTIBODIES INDUCED AGAINST HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
FR8705398 1987-04-15
FR8701739 1987-04-15
DK200201277A DK175879B1 (en) 1987-01-16 2002-08-30 NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components
DK200201277 2002-08-30
DK200301628 2003-11-03
DK200301628A DK176372B1 (en) 1987-01-16 2003-11-03 NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components

Publications (2)

Publication Number Publication Date
DK200301628A true DK200301628A (en) 2003-11-03
DK176372B1 DK176372B1 (en) 2007-10-08

Family

ID=29716190

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200301628A DK176372B1 (en) 1987-01-16 2003-11-03 NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components

Country Status (1)

Country Link
DK (1) DK176372B1 (en)

Also Published As

Publication number Publication date
DK176372B1 (en) 2007-10-08

Similar Documents

Publication Publication Date Title
EP0387914B1 (en) Envelope antigens of the human immuno-deficiency virus, and their applications
Wang et al. Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein.
US8236324B2 (en) Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens
US5030714A (en) Variant of LAV viruses
EP0267802B1 (en) Synthetic antigen for the detection of aids-related disease
US5034511A (en) Variant of LAV viruses
Lal et al. Failure to detect evidence of human T-lymphotropic virus (HTLV) type I and type II in blood donors with isolated gag antibodies to HTLV-I/II
US6492104B1 (en) EIA test using nondenatured HIV antigen for early detection of HIV infection
US6440657B1 (en) Nucleic acids and peptides of human immunodeficiency virus type (HIV-1)
EP0461193B1 (en) Discrimination between antibodies against htlv-i, htlv-ii or related retroviruses, new peptides, detection of antibodies and immunoassay kits
Dorn et al. Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection
US5019510A (en) Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
ATE87487T1 (en) RECOMBINANT HIV-2 POLYPEPTIDES.
EP0439077B1 (en) Synthetic peptide compositions with immunoreactivities to antibodies to HTLV
EP0605433B1 (en) Immunoassay for the simultaneous detection of hiv-1, hiv-2, htlv-i and htlv-ii antibodies
EP0284383B1 (en) Synthetic antigens for the detection of aids-related disease caused by LAV-2
WO1990008162A1 (en) Synthetic peptide compositions with immunoreactivities to antibodies to htlv-1
DK200301628A (en) NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components
DK200201277A (en) NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components
LAL et al. Humoral responses to the immunodominant gag and env epitopes of human T-lymphotropic virus type I among Melanesians
SHERMAN et al. Evaluation of HIV type 1 Western blot-indeterminate blood donors for the presence of human or bovine retroviruses
KR890700603A (en) Peptides Recognized as Antibodies Against Human Immunodeficiency Retrovirus (HIV Virus), and Methods of Use thereof in Diagnosis of Virus Infection and Vaccine Preparation of AIDS
Karpas et al. Use of Karpas HIV cell test to detect antibodies to HIV-2
Lal et al. Analysis of Genetic Variability within the
EP1568767A2 (en) Dna fragments of lav genes

Legal Events

Date Code Title Description
PUP Patent expired